Any current/future new fundraising through debt or equity?

The company currently has a robust balance sheet with a net cash position of Rs. 472 crores as of September 30, 2023. They plan to fund ongoing and planned capital expenditures entirely through internal accruals without any need for debt financing. There is no mention of any current or future plans for fundraising through debt or equity in the transcript. The company is confident of completing all planned capital expenditure via internal funds and cash flows.

Any current/future capex/capital investment/strategic investment?

The company has a robust capital expenditure plan supported by a strong balance sheet with a net cash position of Rs. 472 crores as of September 30, 2023. Approximately Rs. 55 crores was invested in capital expenditures during the recent quarter. Significant expansion is planned in H2 FY24 with the addition of 270 beds via three new hospitals in Hyderabad, Bengaluru, and Chennai to strengthen the Hub and Spoke model. New projects include a 60-bed hospital in Central Hyderabad (launch expected November 14), a 50-bed additional block at Hydernagar, Hyderabad (operational by December), and 80-bed

Future growth expectations in sales/revenue/volumes?

Expansion plans include adding 270 new beds across Hyderabad, Bengaluru, and Chennai in H2 FY24, strengthening the Hub and Spoke model. New hospitals are expected to mature over 4-5 years, reaching occupancy levels of around 50-55%, driving growth in ARPOB, revenue, and EBITDA in coming quarters. Revenue for Q2 FY24 showed 6.3% growth year-on-year; H1 revenue grew 12.7% compared to last year. Patient volumes saw a minor decline (2% outpatient, 1% inpatient) due to seasonal and environmental factors; deliveries grew by 4%. Management targets blended occupancy around 50% including new hospitals

Future growth expectations in earnings/operating earnings/profits/EPS?

Rainbow Children’s Medicare expects growth from new hospitals as they mature, with ARPOB, ALOS, and occupancy reaching levels similar to mature units within 4-5 years. The new hospitals are forecasted to achieve occupancy of around 50%-55% over this period. Addition of 270 new beds in the next five months (by March end) is expected to drive revenue and EBITDA growth. EBITDA margins remain strong at over 35%, supported by case mix and operational leverage. Revenue growth was 6.3% in Q2 FY24 and 12.7% in H1 FY24; EBITDA grew 7.3% (Q2) and 7.1% (H1). PAT growth is more moderate due to increased d

Rainbow Child.Q2 FY24Healthcare Services

Rainbow Child. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,280P/E: 48.7Market Cap: ₹14.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Expansion plans include adding 270 new beds across Hyderabad, Bengaluru, and Chennai in H2 FY24, strengthening the Hub and Spoke model.
New hospitals are expected to mature over 4-5 years, reaching occupancy levels of around 50-55%, driving growth in ARPOB, revenue, and EBITDA in coming quarters.
Revenue for Q2 FY24 showed 6.3% growth year-on-year; H1 revenue grew 12.7% compared to last year.
Patient volumes saw a minor decline (2% outpatient, 1% inpatient) due to seasonal and environmental factors; deliveries grew by 4%.
Management targets blended occupancy around 50% including new hospitals by year-end.
Case mix improvements and price escalations expected to sustain ARPOB growth at 5-6% annually.
International business is growing, now constituting about 4% of revenue, with potential to contribute more in future.
The company expects operating leverage and higher occupancies as key drivers for future revenue and margin expansion.

Margin guidance

Category 3

Rainbow Children’s Medicare expects growth from new hospitals as they mature, with ARPOB, ALOS, and occupancy reaching levels similar to mature units within 4-5 years.
The new hospitals are forecasted to achieve occupancy of around 50%-55% over this period.
Addition of 270 new beds in the next five months (by March end) is expected to drive revenue and EBITDA growth.
EBITDA margins remain strong at over 35%, supported by case mix and operational leverage.
Revenue growth was 6.3% in Q2 FY24 and 12.7% in H1 FY24; EBITDA grew 7.3% (Q2) and 7.1% (H1).
PAT growth is more moderate due to increased depreciation with new units but expected to improve as expansions stabilize.
Full-year ARPOB growth is guided around 5%-6%.
The company foresees break-even for new units in markets like Bangalore and Chennai within 12-18 months, and about 2 years for tier 2 markets like Rajahmundry.
Strong balance sheet with Rs. 472 crore net cash supports capex without debt financing.

See what Rainbow Child. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company currently has a robust balance sheet with a net cash position of Rs. 472 crores as of September 30, 2023.
They plan to fund ongoing and planned capital expenditures entirely through internal accruals without any need for debt financing.
There is no mention of any current or future plans for fundraising through debt or equity in the transcript.
The company is confident of completing all planned capital expenditure via internal funds and cash flows.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Rainbow Children’s Medicare Limited. However, related operational and expansion details include: - There are 270 new beds expected to be commissioned by March 31, 2024, with 110 beds in Hyderabad. - Expansion includes new hospital units nearing readiness (Central Hyderabad opening in 14-15 days, Hydernagar by December). - The company is confident about meeting timelines for these new units and expects growth from these new hospitals as they mature over 4-5 years. - Capital expenditure plans are ongoing, with around Rs. 55 crores invested in the recent quarter. - The company expects to fund future capital expenditures through internal accruals without debt. No direct mention is made about formal order books or contracts related to equipment or services in the transcript.

See what Rainbow Child. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has a robust capital expenditure plan supported by a strong balance sheet with a net cash position of Rs. 472 crores as of September 30, 2023.
Approximately Rs. 55 crores was invested in capital expenditures during the recent quarter.
Significant expansion is planned in H2 FY24 with the addition of 270 beds via three new hospitals in Hyderabad, Bengaluru, and Chennai to strengthen the Hub and Spoke model.
New projects include a 60-bed hospital in Central Hyderabad (launch expected November 14), a 50-bed additional block at Hydernagar, Hyderabad (operational by December), and 80-bed spoke hospitals in Anna Nagar, Chennai and Sarjapur, Bangalore (slated for Q4 FY24).
Future expansions include a 60-bed spoke hospital at Hennur, Bangalore and a 100-bed greenfield spoke hospital at Rajahmundry, Andhra Pradesh, expected to commence in the next financial year.
The company plans to complete all capital expenditures through internal accruals without debt financing.

Track Rainbow Child. — get its next earnings analysis in your feed

How does Rainbow Child. rank vs peers in Healthcare Services?

Pro feature

ThisRainbow Child.

Rev 3Mar 3

See where Rainbow Child. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Rainbow Child. rank in Healthcare Services?

Compare Rainbow Child. against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Rainbow Child.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Rainbow Child. Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Rainbow Child. rank in Healthcare Services?

Continue your research

What Rainbow Child.'s management said in earlier quarters

Others in Healthcare Services this season